CA2953207A1 - Nasal administration - Google Patents

Nasal administration Download PDF

Info

Publication number
CA2953207A1
CA2953207A1 CA2953207A CA2953207A CA2953207A1 CA 2953207 A1 CA2953207 A1 CA 2953207A1 CA 2953207 A CA2953207 A CA 2953207A CA 2953207 A CA2953207 A CA 2953207A CA 2953207 A1 CA2953207 A1 CA 2953207A1
Authority
CA
Canada
Prior art keywords
optionally
nasal
sumatriptan
patient
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2953207A
Other languages
English (en)
French (fr)
Inventor
Per Gisle Djupesland
Ramy A. Mahmoud
John Messina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optinose Inc
Original Assignee
Optinose AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/315,132 external-priority patent/US11554229B2/en
Application filed by Optinose AS filed Critical Optinose AS
Publication of CA2953207A1 publication Critical patent/CA2953207A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2953207A 2014-06-25 2015-06-25 Nasal administration Pending CA2953207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/315,132 2014-06-25
US14/315,132 US11554229B2 (en) 2013-03-26 2014-06-25 Nasal administration
PCT/EP2015/064463 WO2015197798A1 (en) 2014-06-25 2015-06-25 Nasal administration

Publications (1)

Publication Number Publication Date
CA2953207A1 true CA2953207A1 (en) 2015-12-30

Family

ID=53489954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953207A Pending CA2953207A1 (en) 2014-06-25 2015-06-25 Nasal administration

Country Status (14)

Country Link
EP (2) EP4233950B1 (https=)
JP (2) JP6785227B2 (https=)
KR (1) KR102458964B1 (https=)
CN (1) CN106470724A (https=)
AU (3) AU2015279154A1 (https=)
BR (1) BR112016029926A2 (https=)
CA (1) CA2953207A1 (https=)
ES (1) ES3034743T3 (https=)
IL (1) IL249585B (https=)
MX (1) MX390453B (https=)
RU (1) RU2016152090A (https=)
SG (1) SG11201610685XA (https=)
WO (1) WO2015197798A1 (https=)
ZA (1) ZA201608785B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713899D0 (en) * 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN108421138A (zh) * 2017-12-25 2018-08-21 宫本海 一种鼻腔雾化吸药器
US11259717B2 (en) * 2018-05-16 2022-03-01 Massachusetts Institute Of Technology Methods and apparatus for passive, proportional, valveless gas sampling and delivery
US12478292B2 (en) 2019-10-28 2025-11-25 The Research Foundation For The State University Of New York Devices, systems, and methods of monitoring arterial carbon dioxide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB0121568D0 (en) * 2001-09-06 2001-10-24 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
US7017573B1 (en) 1999-07-12 2006-03-28 Capnia, Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
US20070039615A1 (en) * 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
EP1259282A4 (en) 2000-02-28 2007-05-23 Capnia Inc METHOD AND DEVICE FOR THE TRANSCUTANEOUS INFUSION OF CARBON DIOXIDE FOR LOCAL PAIN TREATMENT AND THE TREATMENT OF OTHERS
ZA200306564B (en) * 2001-02-26 2004-10-15 Optinose As Nasal devices.
GB2403154B (en) * 2002-04-04 2007-01-24 Optinose As Nasal devices
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
GB0320171D0 (en) * 2003-08-28 2003-10-01 Optinose As Delivery devices
US20080190418A1 (en) * 2003-08-29 2008-08-14 Glaxo Group Limited Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto
EP1819329A2 (en) * 2004-08-04 2007-08-22 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
GB0503738D0 (en) * 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0602980D0 (en) * 2006-02-14 2006-03-29 Optinose As Delivery device and method
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2440316A (en) * 2006-07-25 2008-01-30 Optinose As Nasal inhaler with scrubber
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
GB2448193A (en) * 2007-04-05 2008-10-08 Optinose As Nasal delivery device
GB0719299D0 (en) * 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
CA2728808A1 (en) * 2008-02-01 2009-08-06 Vectura Limited Pulmonary formulations of triptans
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
BR112014020260A8 (pt) * 2012-02-16 2017-07-11 Capnia Inc Distribuidor de gás com peça nasal de difusão
PL2978482T3 (pl) * 2013-03-26 2022-10-03 Optinose As Podawanie donosowe

Also Published As

Publication number Publication date
MX390453B (es) 2025-03-19
EP4233950C0 (en) 2025-06-25
MX2016017038A (es) 2017-05-01
CN106470724A (zh) 2017-03-01
ES3034743T3 (en) 2025-08-22
RU2016152090A (ru) 2018-07-27
ZA201608785B (en) 2019-10-30
AU2020202029A1 (en) 2020-04-09
KR20170035919A (ko) 2017-03-31
AU2021215246A1 (en) 2021-09-09
BR112016029926A2 (pt) 2017-08-22
JP7090124B2 (ja) 2022-06-23
WO2015197798A1 (en) 2015-12-30
EP3160556A1 (en) 2017-05-03
EP4233950A1 (en) 2023-08-30
JP6785227B2 (ja) 2020-11-18
RU2016152090A3 (https=) 2019-02-15
JP2017520364A (ja) 2017-07-27
JP2020179191A (ja) 2020-11-05
IL249585A0 (en) 2017-02-28
SG11201610685XA (en) 2017-01-27
AU2015279154A1 (en) 2017-01-12
EP4233950B1 (en) 2025-06-25
KR102458964B1 (ko) 2022-10-25
IL249585B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
US20250339632A1 (en) Nasal administration
EP2978482B1 (en) Nasal administration
AU2021215246A1 (en) Nasal Administration
US12491325B2 (en) Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity
US8875704B2 (en) Nasal administration
WO2021245605A1 (en) Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity
JP6945614B2 (ja) 経鼻投与
CA2908232C (en) Nasal administration of fluticasone and carbon dioxide
HK1221672B (en) Nasal administration

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200615

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250710

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250915

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250915